243 related articles for article (PubMed ID: 29558031)
21. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
Moschen AR; Kaser A; Stadlmann S; Millonig G; Kaser S; Mühllechner P; Habior A; Graziadei I; Vogel W; Tilg H
J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
[TBL] [Abstract][Full Text] [Related]
22. Receptor Activator of Nuclear Factor κ-Β Ligand/Osteoprotegerin Axis in Adults with Hb S/β-Thalassemia and β-Thalassemia Trait.
Tombak A; Boztepe B; Akbayir S; Dogru G; Sungur MA
Hemoglobin; 2020 Sep; 44(5):334-337. PubMed ID: 32873083
[TBL] [Abstract][Full Text] [Related]
23. Selected adipose tissue hormones, bone metabolism, osteoprotegerin and receptor activator of nuclear factor-kB ligand in postmenopausal obese women.
Ostrowska Z; Świętochowska E; Marek B; Kajdaniuk D; Tyrpień-Golder K; Wołkowska-Pokrywa K; Damasiewicz-Bodzek A; Kos-Kudła B
Endokrynol Pol; 2014; 65(6):438-48. PubMed ID: 25554611
[TBL] [Abstract][Full Text] [Related]
24. Multiparameter analysis of serum levels of C-telopeptide crosslaps, bone-specific alkaline phosphatase, cathepsin K, osteoprotegerin and receptor activator of nuclear factor κB ligand in the diagnosis of osteoporosis.
Piatek S; Adolf D; Wex T; Halangk W; Klose S; Westphal S; Amthauer H; Winckler S
Maturitas; 2013 Apr; 74(4):363-8. PubMed ID: 23391500
[TBL] [Abstract][Full Text] [Related]
25. Proinflammatory cytokines and receptor activator of nuclear factor kappaB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohn's disease.
Turk N; Cukovic-Cavka S; Korsic M; Turk Z; Vucelic B
Eur J Gastroenterol Hepatol; 2009 Feb; 21(2):159-66. PubMed ID: 19098682
[TBL] [Abstract][Full Text] [Related]
26. The frequency of low bone mineral density and its associated risk factors in patients with inflammatory bowel diseases.
Ezzat Y; Hamdy K
Int J Rheum Dis; 2010 Aug; 13(3):259-65. PubMed ID: 20704624
[TBL] [Abstract][Full Text] [Related]
27. Bone Metabolism and the c.-223C > T Polymorphism in the 5'UTR Region of the Osteoprotegerin Gene in Patients with Inflammatory Bowel Disease.
Krela-Kaźmierczak I; Kaczmarek-Ryś M; Szymczak A; Michalak M; Skrzypczak-Zielińska M; Drwęska-Matelska N; Marcinkowska M; Eder P; Łykowska-Szuber L; Wysocka E; Linke K; Słomski R
Calcif Tissue Int; 2016 Dec; 99(6):616-624. PubMed ID: 27639566
[TBL] [Abstract][Full Text] [Related]
28. Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy.
Miheller P; Muzes G; Rácz K; Blázovits A; Lakatos P; Herszényi L; Tulassay Z
Inflamm Bowel Dis; 2007 Nov; 13(11):1379-84. PubMed ID: 17663430
[TBL] [Abstract][Full Text] [Related]
29. Bone mineral density and inflammatory bowel disease severity.
Lima CA; Lyra AC; Mendes CMC; Lopes MB; Coqueiro FG; Rocha R; Santana GO
Braz J Med Biol Res; 2017 Oct; 50(12):e6374. PubMed ID: 29069227
[TBL] [Abstract][Full Text] [Related]
30. Health care for osteoporosis in inflammatory bowel disease: unmet needs in care of male patients?
Walldorf J; Krummenerl A; Engler K; Busch J; Dollinger MM; Seufferlein T; Albert JG
J Crohns Colitis; 2013 Dec; 7(11):901-7. PubMed ID: 23333038
[TBL] [Abstract][Full Text] [Related]
31. Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?
Kananen K; Volin L; Laitinen K; Ruutu T; Välimäki MJ
Osteoporos Int; 2006; 17(5):724-30. PubMed ID: 16437190
[TBL] [Abstract][Full Text] [Related]
32. Bone mineral density in patients with inflammatory bowel disease from north-eastern Romania.
Dumitrescu G; Mihai C; Dranga M; Prelipcean CC
Rev Med Chir Soc Med Nat Iasi; 2013; 117(1):23-8. PubMed ID: 24505888
[TBL] [Abstract][Full Text] [Related]
33. Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone mineral density.
Hamed EA; Mohamed NA; El-Metwally TH; Kamal MM
J Pediatr Hematol Oncol; 2010 May; 32(4):267-73. PubMed ID: 20445416
[TBL] [Abstract][Full Text] [Related]
34. Gingival crevicular fluid, serum levels of receptor activator of nuclear factor-κB ligand, osteoprotegerin, and interleukin-17 in patients with rheumatoid arthritis and osteoporosis and with periodontal disease.
Gümüş P; Buduneli E; Bıyıkoğlu B; Aksu K; Saraç F; Nile C; Lappin D; Buduneli N
J Periodontol; 2013 Nov; 84(11):1627-37. PubMed ID: 23327689
[TBL] [Abstract][Full Text] [Related]
35. Associations between osteoprotegerin and femoral neck BMD in hemodialysis patients.
Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Stathakis CP; Diamanti-Kandarakis E; Dimitroulis D; Perrea DN
J Bone Miner Metab; 2008; 26(1):66-72. PubMed ID: 18095066
[TBL] [Abstract][Full Text] [Related]
36. Osteoprotegerin, s-RANKL, and selected interleukins in the pathology of bone metabolism in patients with Crohn's disease.
Krela-Kaźmierczak I; Wysocka E; Szymczak A; Eder P; Michalak M; Łykowska-Szuber L; Stawczyk-Eder K; Klimczak K; Linke K; Horst-Sikorska W
Prz Gastroenterol; 2016; 11(1):30-4. PubMed ID: 27110308
[TBL] [Abstract][Full Text] [Related]
37. Role of ghrelin and insulin-like growth factor binding protein-3 in the development of osteoporosis in inflammatory bowel disease.
Koutroubakis IE; Zavos C; Damilakis J; Papadakis G; Neratzoulakis J; Karkavitsas N; Kouroumalis EA
J Clin Gastroenterol; 2011 Jul; 45(6):e60-5. PubMed ID: 20921904
[TBL] [Abstract][Full Text] [Related]
38. Osteoprotegrin interacts with biomarkers and cytokines that have roles in osteoporosis, skin fibrosis, and vasculopathy in systemic sclerosis: A potential multifaceted relationship between OPG/RANKL/TRAIL and Wnt inhibitors.
Taylan A; Birlik M; Kenar G; Toprak B; Gundogdu B; Gurler O; Karakas B; Akıncı B; Sisman AR
Mod Rheumatol; 2019 Jul; 29(4):619-624. PubMed ID: 30001654
[No Abstract] [Full Text] [Related]
39. The balance between soluble receptors regulating IL-6 trans-signaling is predictive for the RANKL/osteoprotegerin ratio in postmenopausal women with rheumatoid arthritis.
Oelzner P; Franke S; Lehmann G; Eidner T; Hein G; Wolf G
Rheumatol Int; 2012 Jan; 32(1):199-206. PubMed ID: 20821212
[TBL] [Abstract][Full Text] [Related]
40. Physical activity, quality of diet and bone mineral density in patients with inflammatory bowel disease.
Ratajczak-Pawłowska AE; Michalak M; Szymczak-Tomczak A; Rychter AM; Zawada A; Skoracka K; Dobrowolska A; Krela-Kaźmierczak I
J Hum Nutr Diet; 2023 Oct; 36(5):1692-1700. PubMed ID: 37403249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
